Clinical Utility Pilot Of Thyroid GuidePx
The purpose of this research study is learn about the effects of Thyroid GuidePx® on papillary thyroid cancer treatment recommendations when the test result is disclosed after surgery.
研究概览
详细说明
Primary Objectives:
To determine the decision impact of Thyroid GuidePx® when results are disclosed postoperatively, defined across three prespecified decision domains:
- Extent of initial surgery (counterfactual): (i) among patients who actually had a total thyroidectomy, through the post-test clinician survey, whether Thyroid GuidePx® results would have changed surgical extent and lobectomy would have been appropriate. This includes patients who underwent intraoperative conversion from lobectomy to total thyroidectomy due to gross extrathyroidal extension or unexpected central nodal metastases. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation.
- Completion thyroidectomy: whether Thyroid GuidePx® results change the recommendation to perform completion thyroidectomy or not to perform completion thyroidectomy.
- Adjuvant RAI: Whether Thyroid GuidePx® results change the recommendation to administer postoperative RAI or not to administer postoperative RAI.
Secondary Objectives:
- To estimate the proportion of decision changes within each prespecified domain and the net direction (escalation vs de-escalation).
- To explore clinician- and patient-reported drivers of decision change.
- To assess postoperative decisional regret following disclosure of Thyroid GuidePx® results using the Decisional Regret Scale (DRS), and to explore associations with surgical extent and molecular risk category.
- To compare the proportion of patients who had a completion thyroidectomy in patients who underwent Thyroid GuidePx® testing to historical controls.
- To compare recurrence outcomes in patients whose treatment was de-escalated based on Thyroid GuidePx® result to matched historical controls at the same institution.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Anastasios Maniakas, MD
- 电话号码:713-792-4351
- 邮箱:amaniakas@mdanderson.org
学习地点
-
-
Texas
-
Houston、Texas、美国、77030
- UT MD Anderson
-
接触:
- Anastasios Maniakas, MD
- 电话号码:713-792-4351
- 邮箱:amaniakas@mdanderson.org
-
首席研究员:
- Anastasios Maniakas, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
UT MD Anderson
描述
Inclusion Criteria:
disease who can potentially be treated with lobectomy will be recruited to the study. Lobectomy-candidate status is determined by the treating physician using standard institutional criteria (e.g., tumor 1-4 cm, cN0/Nx, no gross ETE). Patients may still undergo total thyroidectomy as part of shared decision-making.
Inclusion criteria:
-
Patients aged 18 years or older at the time of enrollment
-
English-speaking
-
Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)
-
Preoperative candidacy for lobectomy
- Tumor 1 - 4 cm in size
- No known nodal metastasis
- No gross extrathyroidal extension (ETE) on ultrasound
-
Any of the following intraoperative or surgeon-dependent variations are permitted:
- Prophylactic ipsilateral central neck dissection performed at the surgeon's discretion
- Therapeutic central neck dissection for unexpected central node metastases
- Intraoperative conversion to total thyroidectomy (e.g., gross ETE, multiple large central nodes)
-
Able to undergo intraoperative FNA collection for research testing
Exclusion Criteria:
- Prior thyroid operation
- Distant metastatic disease
- Personal history of thyroid cancer
- History of whole-body radiation exposure or radiation to the head and neck region
- Preoperatively known central or lateral lymph node metastasis
- Receipt of total thyroidectomy is not an exclusion if preoperative features otherwise meet lobectomy-candidate criteria
Patients remain eligible if unexpected central nodal disease is identified intraoperatively or if the surgeon elects to perform a prophylactic ipsilateral central neck dissection, as these scenarios are compatible with initial lobectomy candidacy at MD Anderson.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
All Patients
Eligible participants will be identified during standard preoperative evaluation for thyroid nodules or confirmed PTC, following cytological diagnosis (Bethesda V or VI). |
Participants will be offered enrollment in this study, in which Thyroid GuidePx® will be performed on an intraoperative FNA (ioFNA) collected during surgery, with results disclosed postoperatively. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Decision Impact. There are three domain-specific endpoints
大体时间:Through study completion; an average of 1 year
|
Extent of initial surgery (counterfactual). (i) Among patients who actually had total thyroidectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, would have changed surgical extent. Specifically, if lobectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential de-escalation. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation. b) Completion thyroidectomy. Proportion with a change in recommendation (Yes→No or No→Yes). c) Adjuvant RAI. Proportion with a change in recommendation (Yes→No or No→Yes) and intended dose if Yes. |
Through study completion; an average of 1 year
|
合作者和调查者
调查人员
- 首席研究员:Anastasios Maniakas, MD、UT MD Anderson
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.